

## RESEARCH ARTICLE

# Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission

Patience Nyakato<sup>1\*</sup>, Mary-Ann Davies<sup>1</sup>, Karl-Gunter Technau<sup>2</sup>, Geoffrey Fatti<sup>3,4</sup>, Helena Rabie<sup>5,6</sup>, Frank Tanser<sup>7,8,9,10</sup>, Andrew Boule<sup>1,11,12</sup>, Robin Wood<sup>1,13</sup>, Brian Eley<sup>14,15</sup>, Shobna Sawry<sup>16</sup>, Janet Giddy<sup>17</sup>, Nosisa Sipambo<sup>18</sup>, Louise Kuhn<sup>19</sup>, Lee Fairlie<sup>16</sup>, for the International epidemiology Database to Evaluate AIDS-Southern Africa (IeDEA-SA) Collaboration<sup>†</sup>



## OPEN ACCESS

**Citation:** Nyakato P, Davies M-A, Technau K-G, Fatti G, Rabie H, Tanser F, et al. (2020) Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE 15(5): e0233693. <https://doi.org/10.1371/journal.pone.0233693>

**Editor:** Luis Menéndez-Arias, Consejo Superior de Investigaciones Científicas, SPAIN

**Received:** September 2, 2019

**Accepted:** May 11, 2020

**Published:** May 29, 2020

**Copyright:** © 2020 Nyakato et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** The data are owned by the sites that participate in the collaboration. All personal medical data are regarded as confidential and sensitive and cannot be shared except under the agreed conditions of IeDEA Southern Africa. This involves a formal concept proposal and approval process, restricted to the specific analysis. Access to data from IeDEA-SA can be requested via the IeDEA-SA website ([www.iedea-sa.org](http://www.iedea-sa.org)) under the "Collaborate with Us" tab. Regional data comprises cohorts within Southern

**1** Center for Infectious Diseases Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa, **2** Empilweni Services and Research Unit, Department of Paediatrics and Child Health, University of the Witwatersrand, Johannesburg, South Africa, **3** Kheth'Impilo AIDS Free Living, Cape Town, Western Cape, South Africa, **4** Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, Cape Town, Western Cape, South Africa, **5** University of Stellenbosch, Stellenbosch, Cape Town, Western Cape, South Africa, **6** Tygerberg Academic Hospital, Cape Town, Western Cape, South Africa, **7** Africa Health Research Institute, KwaZulu-Natal, Durban, South Africa, **8** Lincoln International Institute for Rural Health, University of Lincoln, Lincoln, England, United Kingdom, **9** School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa, **10** Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa, **11** Khayelitsha ART Program, Cape Town, Western Cape, South Africa, **12** Western Cape Department of Health, Cape Town, Western Cape, South Africa, **13** Gugulethu ART Program, Cape Town, Western Cape, South Africa, **14** Red Cross War Memorial Children's Hospital, Cape Town, Western Cape, South Africa, **15** Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, South Africa, **16** Wits Reproductive Health and HIV Institute (Wits RHI), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, **17** McCord Hospital, Durban, South Africa, **18** Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, University of Witwatersrand, Johannesburg, South Africa, **19** Gertrude H Sergievsky Center, College of Physicians and Surgeons and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America

<sup>†</sup> Membership of the International epidemiology Database to Evaluate AIDS-Southern Africa (IeDEA-SA) Collaboration can be found at [www.idea-sa.org](http://www.idea-sa.org)  
\* [patience.nyakato@uct.ac.za](mailto:patience.nyakato@uct.ac.za)

## Abstract

Efavirenz-based first-line regimens have been widely used for children  $\geq 3$  years of age starting antiretroviral therapy, despite possible resistance with prior exposure to non-nucleoside reverse transcriptase inhibitors for prevention of mother-to-child transmission (PMTCT). We used logistic regression to examine the association between PMTCT exposure and viral failure (VF) defined as two consecutive viral loads (VL)  $> 1000$  copies/ml between 6–18 months on ART. Children with previous nevirapine exposure for PMTCT were not at higher risk of VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI: 0.56, 1.11).

Africa and multi-regional data may include data from across all collaborating regions as far as North America and Asia-Pacific. Regional cohorts include sites from South Africa, Zimbabwe, Lesotho, Zambia, Mozambique, and Malawi. A future researcher would therefore have to decide whether they would like to use regional or multi-regional data, and all available data that relates to their research question would be available to them.

**Funding:** Research reported in this manuscript was supported by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health under Award Number U01AI069924. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Competing interests:** The authors have declared that no competing interests exist.

## Introduction

While prevention of mother to child HIV transmission (PMTCT) has greatly reduced the number of new pediatric HIV infections, there are still 1.8 million children <15 years of age living with HIV both due to ongoing mother-to-child transmission, and survival of children living with HIV. Over 80% of these children live in sub-Saharan Africa (SSA) [1]. Despite recommendations and guidelines by World Health Organisation (WHO) to treat all people living with HIV irrespective of age and CD4 count [2], optimal antiretroviral therapy (ART) dosing and formulations across all pediatric weight bands and age groups is still a challenge [3]. Metabolic and pharmacokinetic changes related to child development and puberty may require different dosing requirements for children compared to adults [4]. While dolutegravir (DTG) provides hope for simplification and harmonization of pediatric and adult regimens, it is still also not recommended for younger children below 30 kilograms (kgs) and for some children above three years of age [3–5].

In resource limited settings, efavirenz (EFV) will remain part of first-line pediatric regimens and is likely to continue to be relatively widely used [6]. In addition, EFV may be preferred in children requiring rifampicin-based tuberculosis co-treatment [7] and among female adolescents of child bearing age who are not on any, or have inconsistent use of contraception [8]. EFV has been recommended for older children (>3 years) and adults for several years due to its advantages for long term maintenance, once daily dosing, simplification of co-treatment for tuberculosis and preserving alternative drugs for second-line [9].

However, the number of children living with HIV initiating first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) treatment with pre-treatment drug resistance (PDR) due to prior exposure to maternal or infant PMTCT regimens is a significant challenge [9, 10]. Both NVP and EFV have a low genetic barrier to resistance and nevirapine (NVP) remains part of WHO-recommended infant prophylaxis during breastfeeding. Y181C is the most commonly selected mutation following NVP exposure which confers high-level resistance to NVP and low-level resistance to EFV [10]. Kityo *et al.* reported that 1 in 6 children initiating first line ART (164/278 on EFV, 104/278 on NVP and 10/278 on protease inhibitor (PI)) in Uganda had PDR; children with PDR were 15 times more likely to experience virologic failure compared to those without. Children with prior or unknown PMTCT exposure were more likely to have PDR, and although PDR proportions were high, they may have been underestimated due to archived resistance in older children [11]. Among Nigerian children initiating treatment, 16% had PDR and among these 33% experienced treatment failure by 24 months on treatment [12].

The Nevirapine Resistance trial (NEVEREST III) showed non-inferior virologic outcomes (viral failure or rebound) for children <3 years old initiating lopinavir-based first-line and switching to an EFV-based regimen at 3–5 years of age [9]. In both of these studies very few children had extended infant NVP prophylaxis, so the prevalence of PDR and subsequent virologic outcomes (virologic suppression or failure) on EFV-based first-line in this context are not known.

Our study aimed to investigate the association between PMTCT exposure and viral failure in children aged at least three years starting EFV-based ART using routine data from the International epidemiology Database to Evaluate AIDS-Southern Africa (IeDEA-SA) collaboration.

## Materials and methods

### Study setting and population

We used data from IeDEA-SA, a regional collaboration of adult and pediatric HIV treatment programs [13]. We included all children living with HIV aged 3–13 years who initiated EFV-

based ART between 2004 and 2014 at 10 public sector ART programs in South Africa and who had at least two viral load (VL) measurements from six-18 months on ART.

### Exposure and outcome definition

PMTCT exposure status was recorded as exposed, unexposed or unknown. Actual PMTCT regimens were not consistently recorded but the data contained a variable differentiating between those that had been exposed to PMTCT or not based on mother-to child data linkage. Maternal and child PMTCT regimens from relevant South African national and provincial guidelines over the study period are shown in S1a Table and S1b Table in [S1 File](#).

We defined viral failure (VF) as having two consecutive VLs  $\geq 1000$  copies/ml in the 6–18 months after ART initiation. We further present results for the outcome of VF defined as two consecutive VLS  $\geq 400$  copies/ml in the follow up period. We also present results on virologic non-suppression in S5 Table and S6 Table in [S1 File](#) for both cut offs respectively. This was defined as the maximum viral load above 1000 copies/ml in the 6–18 months window to occur (one line per patient was considered). For children with more than 2 values, the worst (highest) value was considered as either suppressed or unsuppressed depending on whether or not it was above 1000 copies/ml.

### Statistical analysis

Descriptive statistics (means (standard deviation), medians (interquartile range) and proportions) were used to summarize patient characteristics. We examined the association between PMTCT exposure and VF between 6–18 months on ART using logistic regression and adjusting for other patient characteristics including calendar year of ART start. Since no PMTCT was available in the public sector in South Africa before 2000, we assumed that children with unknown PMTCT exposure born before 2000 were PMTCT unexposed.

In sensitivity analyses for those born during or after 2000, we assumed PMTCT exposure for those with unknown exposure was either: (1) all exposed as per South African PMTCT guidelines at the time of the child's birth or (2) all unexposed. Results presented are based on complete case analysis(CCA). Multiple imputation (MI) of missing data on WHO stage and immunosuppression using 10 imputed datasets was also done and the results were combined using Rubin's rules. There was no difference in the results between the CCA and MI for both outcomes of VF (2 consecutive VL  $\geq 1000$  copies/ml or 400 copies/ml respectively) (S2 Table–S4 Table in [S1 File](#)). All analysis was done using STATA version 15.1.

### Ethics

IeDEA-SA cohorts have obtained ethical approval to collect and transfer anonymized data through their respective Institutional Review Boards (IRBs). The IeDEA-SA data centre has approval from the University of Cape Town's IRB (Human Research Ethics Committee (HREC)) to receive and analyse these anonymised data.

### Results

Of the 7,896 children included in the analysis, 3,948 (50%) were girls with a median age at ART start of 7.5 (IQR: 5.3, 10.2) years. Over two thirds 5,282/7,896 (66.9%) of the children had initiated ART with World Health Organisation (WHO) clinical stage 3 or 4 disease, and 2,320 (40.1%) had WHO-defined severe immunosuppression ([Table 1](#)).

Recorded PMTCT exposure was: 5,909 (74.8%) unexposed, 529 (6.7%) exposed and 1,458 (18.5%) unknown. After assuming that those with unknown exposure received PMTCT

**Table 1. Characteristics of children stratified by three prevention of mother-to-child transmission (PMTCT) exposure scenarios: - i) according to clinic records, "unknown" category allocated to ii) PMTCT according to national guidelines at the year of birth (YoB) and iii) not receiving PMTCT.**

	PMTCT exposure status according to the clinic records <sup>§</sup>			Unknown PMTCT allocated to PMTCT exposure according to the year of birth <sup>§</sup>			Unknown PMTCT allocated to no PMTCT exposure <sup>§</sup>		
	No (N = 5909)	Yes (N = 529)	Unknown (N = 1458)	No (N = 6483)	Yes (N = 1413)	Total (N = 7896)	No (N = 7372)	Yes (N = 524)	Total (N = 7896)
Sex, n (%)									
Female	3093 (50.6)	261 (49.3)	1007 (49.5)	3283 (50.6)	682 (48.3)	3965 (50.2)	3706 (50.3)	259 (49.5)	3965 (50.2)
WHO Stage <sup>a</sup> , n (%)									
Stages 1&2	1372 (36.1)	34 (15.0)	274 (26.4)	1472 (35.2)	208 (23.4)	1680 (33.1)	1650 (34.0)	30 (13.6)	1680 (33.1)
Stages 3&4	2434 (64.0)	192 (85.0)	766 (73.7)	2711 (64.8)	681 (76.6)	3392 (66.9)	3200 (66.0)	192 (86.5)	3392 (66.9)
WHO defined immunosuppression*, n (%)									
No	2393 (57.4)	296 (68.4)	773 (65.3)	2682 (57.7)	780 (68.6)	3462 (59.9)	3169 (59.2)	293 (68.1)	3462 (59.9)
Yes	1773 (42.6)	137 (31.6)	410 (34.6)	1963 (42.3)	357 (31.4)	2320 (40.1)	2183 (40.8)	137 (31.9)	2320 (40.1)
Year of antiretroviral therapy (ART) start, n (%)									
2004–2005	925 (15.1)	20 (3.8)	319 (15.7)	979 (15.1)	75 (5.3)	1054 (13.4)	1034 (14.0)	20 (3.8)	1054 (13.4)
2006–2007	1076 (17.6)	81 (15.3)	530 (26.0)	1176 (18.1)	252 (17.9)	1428 (18.1)	1348 (18.3)	80 (15.3)	1428 (18.1)
2008–2009	1236 (20.2)	159 (30.1)	563 (27.7)	1338 (20.6)	417 (29.5)	1755 (22.2)	1598 (21.7)	157 (30.0)	1755 (22.2)
2010–2011	1252 (20.5)	155 (29.3)	395 (19.4)	1328 (20.5)	386 (27.3)	1714 (21.7)	1560 (21.2)	154 (29.5)	1714 (21.7)
2012–2014	1625 (26.6)	114 (21.6)	228 (11.2)	1663 (25.7)	282 (20.0)	1945 (24.6)	1833 (24.9)	112 (21.4)	1945 (24.6)
Year of birth, n (%)									
Before 2000	1668 (31.3)	0 (0.0)	782 (38.4)	2450 (37.8)	0 (0.0)	2450 (1.0)	2450 (33.2)	0 (0.0)	2450 (31.0)
2000–2003	2184 (40.9)	239 (45.2)	829 (40.7)	2554 (39.4)	698 (49.4)	3252 (41.2)	3016 (40.9)	236 (45.1)	3252 (41.2)
2004–2005	685 (12.9)	171 (32.3)	271 (13.3)	685 (10.6)	442 (31.2)	1127 (14.3)	958 (13.0)	169 (32.3)	1127 (14.3)
2006–2007	479 (9.0)	69 (13.0)	111 (5.5)	479 (7.4)	180 (12.8)	659 (8.4)	591 (8.0)	68 (13.0)	659 (8.4)
2008–2009	248 (4.7)	46 (8.7)	35 (1.7)	248 (3.8)	81 (5.7)	329 (4.2)	283 (3.8)	46 (8.8)	329 (4.2)
2010 and beyond	68 (1.3)	4 (0.8)	7 (0.3)	68 (1.1)	11 (0.8)	79 (1.0)	75 (1.0)	4 (0.8)	79 (1.0)
Weight for age Z- score, (Mean (SD))	-1.68 (1.30)	-1.61 (1.22)	-1.39 (1.22)	-1.48 (1.30)	-1.28 (1.26)	-1.43 (1.29)	-1.44 (1.31)	-1.37 (1.21)	-1.43 (1.29)
Age at ART start, (years, median (IQR))	8.29 (5.89, 10.71)	5.45 (3.98, 6.63)	5.78 (4.29, 7.69)	8.24 (5.89, 10.65)	5.16 (3.91, 6.73)	7.52 (5.25, 10.18)	7.81 (5.42, 10.33)	5.08 (4.0, 6.63)	7.52 (5.25, 10.18)
PMTCT infant drug, n (%)									
sdNVP		480 (90.6)			1329 (94.1)			479 (91.6)	
sdNVP+AZT		42 (7.9)			76 (5.4)			42 (8.0)	
NVP 6 weeks		2 (0.4)			7 (0.5)			2 (0.4)	
Unknown		5 (1.0)	2035 (100.0)						
Maternal PMTCT regimen, n (%)									
sdNVP	0 (0.0)	474 (89.6)	0 (0.0)		1285 (91.0)			474 (90.6)	
sdNVP + AZT	0 (0.0)	45 (8.5)	0 (0.0)		126 (8.9)			45 (8.6)	
AZT only	0 (0.0)	10 (1.9)	2035 (100.0)	1 (0.0)	0 (0.0)		1 (0.01)	0 (0.0)	

<sup>§</sup>Children born before 2000 with unknown PMTCT exposure (n = 782) assumed to get no PMTCT as no PMTCT was available in the public sector before 2000.

<sup>a</sup>Missing observations for 2824/ 7896 (35.8%),

\*Missing observations for 2114/7896 (26.8%) of children of children

<https://doi.org/10.1371/journal.pone.0233693.t001>

according to the year of birth, there were a total of 17.9% (1,413/7896) exposed. Overall, VF was experienced by 1,224/7896 (15.5%) in the period of 6–18 months on ART, and among these, 1,021 (83.4%) had no PMTCT exposure, 61 (5.0%) had been exposed to PMTCT and 142 (11.6%) had unknown exposure to PMTCT.

**Table 2. Univariable and multivariable models of association between prevention of mother-to-child transmission (PMTCT) exposure and viral failure (VF) defined as two consecutive viral load (VL)  $\geq 1000$  copies/ml between 6–18 months on ART: Analysis based on 5782 patients.**

Patient characteristics at ART start	Univariable associations		No assumptions made for unknown PMTCT <sup>§</sup>		Assumption I: Unknown got PMTCT according to year of birth		Assumption II: Unknown assumed not to have got any PMTCT	
	Crude OR*	95% CI**	Adjusted OR*	95% CI**	Adjusted OR*	95% CI**	Adjusted OR*	95% CI**
PMTCT exposure status								
No	1		1		1		1	
Yes	0.62	0.47, 0.82	0.79	0.56, 1.11	0.66	0.52, 0.85	0.91	0.65, 1.27
Unknown	0.52	0.43, 0.62	0.55	0.43, 0.69				
Sex								
Male	1		1		1		1	
Female	0.96	0.85, 1.08	0.94	0.81, 1.09	0.94	0.81, 1.09	0.94	0.81, 1.10
WHO Stage								
Stages 1&2	1							
Stages 3&4	1.06	0.91, 1.24						
WHO-defined Immunosuppression								
No	1		1		1		1	
Yes	2.14	1.82, 2.53	1.75	1.50, 2.04	1.75	1.51, 2.04	1.76	1.51, 2.04
Calendar Year of ART start								
2004–2005	1		1		1		1	
2006–2007	0.87	0.69, 1.09	0.88	0.68, 1.15	0.86	0.66, 1.12	0.83	0.64, 1.08
2008–2009	0.64	0.51, 0.81	0.62	0.45, 0.84	0.60	0.44, 0.82	0.57	0.42, 0.77
2010–2011	1.45	1.18, 1.79	1.54	1.08, 2.17	1.48	1.05, 2.09	1.39	0.99, 1.96
2012–2014	1.34	1.09, 1.64	1.28	0.82, 1.97	1.24	0.80, 1.91	1.19	0.77, 1.84
Year of birth								
Before 2000	1		1		1		1	
2000–2003	0.82	0.71, 0.94	0.84	0.64, 1.10	0.83	0.64, 1.09	0.80	0.61, 1.05
2004–2005	0.60	0.49, 0.74	0.72	0.46, 1.13	0.78	0.50, 1.21	0.73	0.47, 1.13
2006–2007	0.72	0.57, 0.92	0.85	0.49, 1.46	0.92	0.53, 1.58	0.89	0.52, 1.53
2008 and beyond	0.76	0.57, 1.02	1.00	0.50, 1.99	1.12	0.56, 2.21	1.11	0.56, 2.19
Age at ART start in years	1.12	1.10, 1.15	1.05	0.99, 1.11	1.06	1.00, 1.11	1.07	1.02, 1.13

<sup>§</sup>Children born before 2000 with unknown PMTCT exposure (n = 782) assumed to get no PMTCT as no PMTCT available in the public sector before 2000

\*Odds Ratios.

\*\* Confidence Intervals.

<sup>#</sup>All models have been adjusted for sex, immunosuppression at ART start, calendar of ART start, year of birth and age at ART start

<https://doi.org/10.1371/journal.pone.0233693.t002>

After adjusting for immunosuppression, calendar year at ART start, age at ART start as a continuous variable and the year of birth (Table 2), children with previous PMTCT exposure did not have higher odds of experiencing VF compared to unexposed children (adjusted Odds Ratio (aOR): 0.79; 95% CI: 0.56, 1.11). In sensitivity analyses, after assuming children with unknown PMTCT exposure received PMTCT according to South African guidelines at the time and adjusting for the above covariates, there continued to be no evidence of increased odds of VF in PMTCT exposed compared to unexposed children (aOR:0.66; 95%CI: 0.52,0.85). Likewise, if those of unknown PMTCT exposure were assumed to have received no PMTCT, there was also no evidence of increased odds of VF (aOR:0.91; 95% CI: 0.65, 1.27) respectively. Furthermore, sensitivity analysis looking at a cut off of  $\geq 400$  copies/ml for VF yielded similar results (S3 Table in S1 File).

## Discussion

Our study showed no evidence of an increased risk of VF among children who were exposed to PMTCT starting EFV-based ART at  $\geq 3$  years of age. There continued to be no evidence of an increased risk in a sensitivity analysis assuming children with unknown PMTCT exposure either received no PMTCT or received the PMTCT regimen available at the time of their birth.

Our results concur with the NEVEREST III randomized clinical trial (RCT) which randomized PMTCT-exposed children to an EFV-based regimen or to continue lopinavir/ritonavir-based ART [9]. This trial showed no increased risk of VF when virologically-suppressed children above three years old on lopinavir-based regimens with prior single dose NVP-based PMTCT exposure were switched to EFV-based regimens. Podjane *et al* in Thailand also found a similar association of no difference in VF risk based on PMTCT exposure, with a quarter of the children with and without PMTCT exposure experiencing VF during the study period [14].

As children had to be at least three years old at ART start to initiate an EFV-based regimen according to South African guidelines, there were only 11 children with documented PMTCT exposure after the introduction of extended infant NVP prophylaxis, hence we were unable to determine the effect of prolonged infant NVP on outcomes for subsequent EFV-based ART, although none of the 11 children experienced VF. Nonetheless, it is hypothesized that since a single mutation confers EFV resistance and almost all single-dose NVP-exposed infants harbour one of these mutations, longer durations of infant NVP are unlikely to worsen subsequent EFV-based ART outcomes. While some studies have suggested worse outcomes for PMTCT-exposed children on NNRTI-based ART, most PMTCT-exposed children in these studies would have been treated with NVP-based rather than EFV-based ART [15, 16].

Regardless of our findings, the high prevalence of HIV drug resistance to NNRTIs, as a result of the low genetic barrier to resistance, is a major challenge with NNRTI use, specifically EFV, and children receiving EFV should be closely monitored for adherence and viral suppression.

Even with the increasing rollout of DTG for treatment of children living with HIV, many resource-limited settings in SSA and Asia will continue to use EFV in younger children and women or adolescent girls of child bearing age. In addition to the concerns regarding resistance, EFV is reported to have adverse side effects like central nervous system toxicity although this is more mild in children than it is in adults [17]. There are also additional potential side effects such as impaired concentration, skin rash, dizziness, sleep disturbances and anxiety [18, 19]. PI-based first line therapy may offer better outcomes compared to the NNRTIs [20–22]. It is important to have options for first line ART in children and challenges with lopinavir/ritonavir include poor palatability, increased abdominal side effects (diarrhoea and nausea), drug-drug interactions with rifampicin co-treatment and the increased cost and lack of improved paediatric formulations.

Our study had several limitations. Although we adjusted for pre-ART patient characteristics and calendar time, there may be other factors (structural, clinical or psychosocial) related to access to PMTCT that are also associated with better ART outcomes. While this may partially explain the reduced VF associated with PMTCT exposure when assuming that all children with unknown PMTCT exposure received PMTCT according to the year of birth, these factors may also have introduced confounding and potentially masked an association between PMTCT and worse ART response. In addition, since we relied on routinely collected cohort data, we did not have data on other variables that may impact the outcome such as adherence, breastfeeding and cotrimoxazole use, so could not adjust for these variables. We also do not have data regarding the reasons for failing PMTCT. We also only included children that had  $\geq 2$  VL measurement between 6 and 18 months on ART. This

may have introduced selection bias given there may be children who potentially experienced VF but had  $<2$  VL results.

While the use of data from routine care settings in South Africa makes our results generalizable, the recording of PMTCT exposure in routine program data was incomplete, although data completeness improved in more recent calendar years. Additionally, actual maternal and infant regimens were not recorded except for two facilities where we could link the child to the maternal ART file. Notwithstanding, analyses using recorded PMTCT exposure and assumed exposure based on year of birth both did not show an adverse effect of PMTCT exposure on VF. Further, the resistance profile of children in a Ugandan study suggests that a large proportion of children with unknown PMTCT exposure were likely exposed, supporting our sensitivity analysis approach [11].

In conclusion, our finding of no evidence of increased risk of VF among PMTCT exposed children initiating first line EFV-based regimens is reassuring given that EFV-based regimens have been widely used in children living with HIV, and may continue to be used until DTG is registered and accessible for younger children, and in children requiring tuberculosis co-treatment. However, the impact of extended infant NVP prophylaxis on the virologic efficacy of subsequent EFV-based ART remains to be fully assessed.

## Supporting information

**S1 File. Supplementary files for the association between virologic response and prevention of mother to child transmission (PMTCT) exposure among children initiated on efavirenz (EFV) based regimen.**

(DOCX)

## Acknowledgments

We would like to thank all the patients and staff at the sites whose data was used in this analysis. We would also like to thank the data managers and site investigators for harmonizing and putting together the data.

## Author Contributions

**Conceptualization:** Louise Kuhn, Lee Fairlie.

**Formal analysis:** Patience Nyakato.

**Funding acquisition:** Mary-Ann Davies.

**Methodology:** Patience Nyakato, Mary-Ann Davies, Louise Kuhn, Lee Fairlie.

**Resources:** Mary-Ann Davies.

**Software:** Patience Nyakato.

**Supervision:** Mary-Ann Davies.

**Validation:** Mary-Ann Davies, Lee Fairlie.

**Visualization:** Patience Nyakato, Lee Fairlie.

**Writing – original draft:** Patience Nyakato, Lee Fairlie.

**Writing – review & editing:** Patience Nyakato, Mary-Ann Davies, Karl-Gunter Technau, Geoffrey Fatti, Helena Rabie, Frank Tanser, Andrew Boulle, Robin Wood, Brian Eley, Shobna Sawry, Janet Giddy, Nosisa Sipambo, Louise Kuhn, Lee Fairlie.

## References

1. UNAIDS JUNPoHA. Miles to go—Closing gaps, breaking barriers, righting injustices. 2018.
2. ANTIRETROVIRAL TS. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.
3. Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, et al. Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. *Therapeutic drug monitoring*. 2019; 41(4):431.
4. Dehority W, Abadi J, Wiznia A, Viani RM. Use of integrase inhibitors in HIV-infected children and adolescents. *Drugs*. 2015; 75(13):1483–97.
5. Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. *The Pediatric infectious disease journal*. 2015; 34(11):1207.
6. Organization WH. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization; 2018.
7. Rabie H, Decloedt EH, Garcia-Prats AJ, Cotton MF, Frigati L, Lallemand M, et al. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. *Expert opinion on pharmacotherapy*. 2017; 18(6):589–98.
8. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. *The New England journal of medicine*. 2018; 379(10):979.
9. Coovadia A, Abrams EJ, Strehlau R, Shiao S, Pinillos F, Martens L, et al. Efavirenz-based antiretroviral therapy among nevirapine-exposed HIV-infected children in South Africa: a randomized clinical trial. *Jama*. 2015; 314(17):1808–17.
10. Kuhn L, Hunt G, Technau K-G, Coovadia A, Ledwaba J, Pickerill S, et al. Drug resistance among newly-diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. *AIDS (London, England)*. 2014; 28(11):1673.
11. Kityo C, Boerma RS, Sigaloff KC, Kaudha E, Calis JC, Musiime V, et al. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. *Journal of Antimicrobial Chemotherapy*. 2017; 72(9):2587–95.
12. Boerma RS, Boender TS, Sigaloff KC, Rinke de Wit TF, Van Hensbroek MB, Ndambi N, et al. High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children. *Journal of the International AIDS Society*. 2016; 19(1):21140.
13. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. *International Journal of Epidemiology*. 2012; 41(5):1256–64.
14. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *The Pediatric infectious disease journal*. 2009; 28(9):826–30.
15. Mutwa PR, Boer KR, Asimwe-Kateera B, Tuyishimire D, Muganga N, Lange JM, et al. Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: A prospective study. *PloS one*. 2014; 9(11):e111948.
16. Davies M-A, Moultrie H, Eley B, Rabie H, Van Cutsem G, Giddy J, et al. Virologic failure and second-line antiretroviral therapy in children in South Africa—The IeDEA Southern Africa Collaboration. *Journal of acquired immune deficiency syndromes (1999)*. 2011; 56(3):270.
17. Van de Wijer L, Schellekens AF, Burger DM, Homberg JR, de Mast Q, van der Ven AJ. Rethinking the risk–benefit ratio of efavirenz in HIV-infected children. *The Lancet Infectious Diseases*. 2016; 16(5):e76–e81.
18. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, et al. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2015; 69(4):422–9.
19. Larru B, Eby J, Lowenthal ED. Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. *Pediatric health, medicine and therapeutics*. 2014; 5:29.
20. Boerma RS, Boender TS, Van Hensbroek MB, Rinke de Wit TF, Sigaloff KC. Sequencing paediatric antiretroviral therapy in the context of a public health approach. *Journal of the International AIDS Society*. 2015; 18:20265.



21. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *New England Journal of Medicine*. 2010; 363(16):1510–20.
22. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. *New England Journal of Medicine*. 2012; 366(25):2380–9.